Product Information
REYVOW 50 MG TABLET is a brand product labeled by Eli Lilly and Company, priced at $88.6973 per EA under NDC 00002431208. Its NADAC has been published 259 times since Oct 20, 2021.
FDA first approved this application on Jan 31, 2020.
Strength
50 mg/1
Manufacturer
Eli Lilly and CompanyNDC
00002431208
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
5/20/2026
Active Ingredients
LASMIDITANApproval Type
New Drug (NDA)
FDA Application
NDA211280FDA Approved
1/31/2020
On Market Since
10/11/2019
Price Statistics
The NADAC for REYVOW 50 MG TABLET has been published 259 times since Oct 20, 2021, and over the history we have for it it has risen 10.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $88.6973 per EA |
|---|---|
| All-time high | $88.8093 (Dec 10, 2025) |
| All-time low | $80.4875 (Oct 20, 2021) |
| 52-week high | $88.8093 |
| 52-week low | $88.6919 |
| Median price | $88.6919 |
| Average price | $87.4816 |
| Largest weekly change | +5.0% (Jan 12, 2022) |
| Weeks tracked | 259 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lasmiditan market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eli Lilly and Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lasmiditan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of REYVOW 50 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for REYVOW 50 MG TABLET, manufactured by Eli Lilly and Company, is $88.6973 per EA (NDC 00002431208), effective Sep 30, 2026.
How has the price of REYVOW 50 MG TABLET changed over time?
Over the history we have for it, the NADAC for REYVOW 50 MG TABLET has risen 10.2%. It has been tracked across 259 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for REYVOW 50 MG TABLET?
Since Oct 20, 2021, the NADAC for REYVOW 50 MG TABLET has ranged from a low of $80.4875 (Oct 20, 2021) to a high of $88.8093 (Dec 10, 2025), with a median of $88.6919 per EA.
Are there cheaper alternatives to REYVOW 50 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of REYVOW 50 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures REYVOW 50 MG TABLET?
REYVOW 50 MG TABLET (NDC 00002431208) is labeled by Eli Lilly and Company, and CMS classifies it as a brand product.